XML 37 R26.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Reporting (Tables)
3 Months Ended
Mar. 31, 2025
Segment Reporting  
Schedule of segment significant expense categories

The table below is a summary of the segment loss, including significant segment expenses (in thousands):

    

Three Months Ended March 31, 

2025

2024

Grant income

$

5,086

$

4,912

Less:

 

 

Clinical programs

6,877

6,398

R&D Personnel costs(1)

2,792

2,626

Preclinical programs

85

235

Manufacturing

637

1,004

Other research and development expenses

85

59

General and administrative expenses(2)

2,713

2,609

Equity-based compensation

586

1,171

Other segment items(3)

 

(209)

 

(39)

Segment and consolidated net loss

$

(8,480)

$

(9,151)

(1) R&D Personnel costs exclude equity-based compensation

(2) General and administrative expenses exclude equity-based compensation

(3) Other segment items include, Other income, net, Interest expense and Loss on currency translation from liquidation of subsidiary.